Upsher-Smith launches Fluvoxamine Maleate Extended-Release Capsules

MAPLE GROVE, Minn. — Upsher-Smith Laboratories, LLC announced the commercial launch of Fluvoxamine Maleate Extended-Release Capsules in 100 mg and 150 mg strengths, according to a release published on Sept. 30, 2026. The rollout expands the specialized product portfolio managed by the Minnesota-based pharmaceutical company.

Strategic Context

The product introduction places new extended-release psychiatric formulations into the distribution channel following Upsher-Smith’s integration into its parent organization, Bora Pharmaceuticals Co., Ltd., which trades publicly under ticker symbols 6472.TW and BORAY.OTCQX. The operational expansion builds upon Bora Pharmaceuticals' acquisition of the U.S. pharmaceutical platform, aimed at strengthening its North American manufacturing and commercial footprint.

Financial & Macro Implications

The newly available 100 mg and 150 mg dosage strengths provide institutional purchasers, wholesalers, and retail pharmacy networks with an alternative sourcing option for central nervous system therapies. Supply chain managers and procurement officers must factor the new equivalents into inventory planning for psychiatric medications as initial shipments move through primary distribution channels.

Additional commercial and product details were outlined in the official announcement distributed via PR Newswire.

Forward Outlook

Procurement teams across hospital systems and retail pharmacies will observe fill rates, wholesale pricing dynamics, and supply stability as the 100 mg and 150 mg capsules establish market presence. Future portfolio expansions or additional dosage introductions from Upsher-Smith will rely on ongoing regulatory submissions and the continued execution of Bora Pharmaceuticals' U.S. commercial strategy.